References

E. Strong (ed.). Gastric cancer. Principles and practice. Springer (2015)


  1. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J Clin. 2013;63(1):11–30.
  2. Everett SM, Axon AT. Early gastric cancer in Europe. Gut. 1997;41(2):142–50.
  3. Folli S, Dente M, Dell’Amore D, Gaudio M, Nanni O, Saragoni L, et al. Early gastric cancer: prognostic factors in 223 patients. Br J Surg. 1995;82(7):952–6.
  4. Hisamichi S. Screening for gastric cancer. World J Surg. 1989;13(1):31–7.
  5. Sue-Ling HM, Martin I, Griffith J, Ward DC, Quirke P, Dixon MF, et al. Early gastric cancer: 46 cases treated in one surgical department. Gut. 1992;33(10):1318–22.
  6. Blot WJ, Devesa SS, Kneller RW, Fraumeni JF Jr. Rising incidence of adenocarcinoma of the esophagus and gastric cardia. JAMA. 1991;265(10):1287–9.
  7. Lewin K, Appelman H. Carcinoma of the stomach. In: Lewin K, Appelman H, editors. Atlas of tumor pathology: tumors of the esophagus and stomach. Washington, DC: Armed Forces Institute of Pathology; 1996. pp. 245–330.
  8. Morales TG. Adenocarcinoma of the gastric cardia. Dig Dis. 1997;15(6):346–56.
  9. Cameron AJ, Lomboy CT, Pera M, Carpenter HA. Adenocarcinoma of the esophagogastric junction and Barrett’s esophagus. Gastroenterology. 1995;109(5):1541–6.
  10. Clark GWB. Is Barrett’s metaplasia the source of adenocarcinomas of the cardia? Arch Surg. 1994;129(6):609.
  11. Wijnhoven BP, Siersema PD, Hop WC, van Dekken H, Tilanus HW. Adenocarcinomas of the distal oesophagus and gastric cardia are one clinical entity. Rotterdam Oesophageal Tumour Study Group. Br J Surg. 1999;86(4):529–35.
  12. Kalish RJ, Clancy PE, Orringer MB, Appelman HD. Clinical, epidemiologic, and morphologic comparison between adenocarcinomas arising in Barrett’s esophageal mucosa and in the gastric cardia. Gastroenterology. 1984;86(3):461–7.
  13. Safatle-Ribeiro AV, Ribeiro U Jr, Reynolds JC. Gastric stump cancer: what is the risk? Dig Dis. 1998;16(3):159–68.
  14. Toftgaard C. Gastric cancer after peptic ulcer surgery. A historic prospective cohort investigation. Ann Surg. 1989;210(2):159–64.
  15. Kaminishi M, Shimizu N, Yamaguchi H, Hashimoto M, Sakai S, Oohara T. Different carcinogenesis in the gastric remnant after gastrectomy for gastric cancer. Cancer. 1996;77(8 Suppl):1646–53.
  16. Taylor PR, Mason RC, Filipe MI, Vaja S, Hanley DC, Murphy GM, et al. Gastric carcinogenesis in the rat induced by duodenogastric reflux without carcinogens: morphology, mucin histochemistry, polyamine metabolism, and labelling index. Gut. 1991;32(12):1447–54.
  17. Kuipers EJ, Uyterlinde AM, Pena AS, Roosendaal R, Pals G, Nelis GF, et al. Long-term sequelae of Helicobacter pylori gastritis. Lancet. 1995;345(8964):1525–8.
  18. Siurala M, Sipponen P, Kekki M. Chronic gastritis: dynamic and clinical aspects. Scand J Gastroenterol Suppl. 1985;109:69–76.
  19. Forman D, Newell DG, Fullerton F, Yarnell JWG, Stacey AR, Wald N, et al. Association between infection with Helicobacter-pylori and risk of gastriccancer—evidence from a prospective investigation. BMJ. 1991;302(6788):1302–5.
  20. Nomura A, Stemmermann GN, Chyou PH, Kato I, Perez-Perez GI, Blaser MJ. Helicobacter pylori infection and gastric carcinoma among Japanese Americans in Hawaii. N Engl J Med. 1991;325(16):1132–6.
  21. Parsonnet J, Friedman GD, Vandersteen DP, Chang Y, Vogelman JH, Orentreich N, et al. Helicobacter pylori infection and the risk of gastric carcinoma. N Engl J Med. 1991;325(16):1127–31.
  22. Gologan A, Graham DY, Sepulveda AR. Molecular markers in Helicobacter pylori-associated gastric carcinogenesis. Clin Lab Med. 2005;25(1):197–222.
  23. Beales IL, Davey NJ, Pusey CD, Lechler RI, Calam J. Long-term sequelae of Helicobacter pylori gastritis. Lancet. 1995;346(8971):381–2.
  24. Goodman KJ, Correa P, Tengana Aux HJ, DeLany JP, Collazos T. Nutritional factors and Helicobacter pylori infection in Colombian children. J Pediatr Gastroenterol Nutr. 1997;25(5):507–15.
  25. Fukayama M, Chong JM, Kaizaki Y. Epstein– Barr virus and gastric carcinoma. Gastric Cancer. 1998;1(2):104–14.
  26. Kang GH, Lee S, Kim WH, Lee HW, Kim JC, Rhyu MG, et al. Epstein–Barr virus-positive gastric carcinoma demonstrates frequent aberrant methylation of multiple genes and constitutes CpG island methylator phenotype-positive gastric carcinoma. Am J Pathol. 2002;160(3):787–94.
  27. Matsusaka K, Kaneda A, Nagae G, Ushiku T, Kikuchi Y, Hino R, et al. Classification of Epstein– Barr virus-positive gastric cancers by definition of DNA methylation epigenotypes. Cancer Res. 2011;71(23):7187–97.
  28. Geddert H, Zur Hausen A, Gabbert HE, Sarbia M. EBV-infection in cardiac and non-cardiac gastric adenocarcinomas is associated with promoter methylation of p16, p14 and APC, but not hMLH1. Anal Cell Pathol (Amst). 2010;33(3):143–9.
  29. Cancer Genome Atlas Research N. Comprehensive molecular characterization of gastric adenocarcinoma. Nature. 2014;513(7517):202–9.
  30. Hsing AW, Hansson LE, McLaughlin JK, Nyren O, Blot WJ, Ekbom A, et al. Pernicious anemia and subsequent cancer. A population-based cohort study. Cancer. 1993;71(3):745–50.
  31. Gladdy RA, Strong VE, Coit D, Allen PJ, Gerdes H, Shia J, et al. Defining surgical indications for type I gastric carcinoid tumor. Ann Surg Oncol. 2009;16(11):3154–60.
  32. Kim J, Cho YA, Choi WJ, Jeong SH. Gene-diet interactions in gastric cancer risk: a systematic review. World J Gastroenterol. 2014;20(28):9600–10.
  33. Palli D. Epidemiology of gastric cancer: an evaluation of available evidence. J Gastroenterol. 2000;35(Suppl 12):84–9.
  34. Hu Z, Ajani JA, Wei Q. Molecular epidemiology of gastric cancer: current status and future prospects. Gastrointest Cancer Res. 2007;1(1):12–9.
  35. Correa P. Diet modification and gastric cancer prevention. J Natl Cancer Inst Monogr. 1992(12):75–8.
  36. Kikugawa K, Kato T, Takeda Y. Formation of a highly mutagenic diazo compound from the bamethan-nitrite reaction. Mutat Res. 1987;177(1):35–43.
  37. Mirvish SS, Grandjean AC, Moller H, Fike S, Maynard T, Jones L, et al. N-nitrosoproline excretion by rural Nebraskans drinking water of varied nitrate content. Cancer Epidemiol Biomarkers Prev. 1992;1(6):455–61.
  38. Masciari S, Dewanwala A, Stoffel EM, Lauwers GY, Zheng H, Achatz MI, et al. Gastric cancer in individuals with Li–Fraumeni syndrome. Genet Med. 2011;13(7):651–7.
  39. Gayther SA, Gorringe KL, Ramus SJ, Huntsman D, Roviello F, Grehan N, et al. Identification of germline E-cadherin mutations in gastric cancer families of European origin. Cancer Res. 1998;58(18):4086–9.
  40. Guilford P, Hopkins J, Harraway J, McLeod M, McLeod N, Harawira P, et al. E-cadherin germline mutations in familial gastric cancer. Nature. 1998;392(6674):402–5.
  41. Guilford PJ, Hopkins JB, Grady WM, Markowitz SD, Willis J, Lynch H, et al. E-cadherin germline mutations define an inherited cancer syndrome dominated by diffuse gastric cancer. Hum Mutat. 1999;14(3):249–55.
  42. Keller G, Vogelsang H, Becker I, Hutter J, Ott K, Candidus S, et al. Diffuse type gastric and lobular breast carcinoma in a familial gastric cancer patient with an E-cadherin germline mutation. Am J Pathol. 1999;155(2):337–42.
  43. Blair V, Martin I, Shaw D, Winship I, Kerr D, Arnold J, et al. Hereditary diffuse gastric cancer: diagnosis and management. Clin Gastroenterol Hepatol. 2006;4(3):262–75.
  44. Caldas C, Carneiro F, Lynch HT, Yokota J, Wiesner GL, Powell SM, et al. Familial gastric cancer: overview and guidelines for management. J Med Genet. 1999;36(12):873–80.
  45. Pharoah PD, Guilford P, Caldas C, International Gastric Cancer Linkage Consortium. Incidence of gastric cancer and breast cancer in CDH1 (E-cadherin) mutation carriers from hereditary diffuse gastric cancer families. Gastroenterology. 2001;121(6):1348–53.
  46. Huntsman DG, Carneiro F, Lewis FR, MacLeod PM, Hayashi A, Monaghan KG, et al. Early gastric cancer in young, asymptomatic carriers of germ-line E-cadherin mutations. N Engl J Med. 2001;344(25):1904–9.
  47. Abraham SC, Nobukawa B, Giardiello FM, Hamilton SR, Wu TT. Fundic gland polyps in familial adenomatous polyposis: neoplasms with frequent somatic adenomatous polyposis coli gene alterations. Am J Pathol. 2000;157(3):747–54.
  48. Hofgartner WT, Thorp M, Ramus MW, Delorefice G, Chey WY, Ryan CK, et al. Gastric adenocarcinoma associated with fundic gland polyps in a patient with attenuated familial adenomatous polyposis. Am J Gastroenterol. 1999;94(8):2275–81.
  49. Offerhaus GJ, Entius MM, Giardiello FM. Upper gastrointestinal polyps in familial adenomatous polyposis. Hepatogastroenterology. 1999;46(26):667–9.
  50. Watanabe H, Enjoji M, Yao T, Ohsato K. Gastric lesions in familial adenomatosis coli: their incidence and histologic analysis. Hum Pathol. 1978;9(3):269–83.
  51. Zwick A, Munir M, Ryan CK, Gian J, Burt RW, Leppert M, et al. Gastric adenocarcinoma and dysplasia in fundic gland polyps of a patient with attenuated adenomatous polyposis coli. Gastroenterology. 1997;113(2):659–63.
  52. Abraham SC, Montgomery EA, Singh VK, Yardley JH, Wu TT. Gastric adenomas: intestinal-type and gastric-type adenomas differ in the risk of adenocarcinoma and presence of background mucosal pathology. Am J Surg Pathol. 2002;26(10):1276–85.
  53. Arnason T, Liang WY, Alfaro E, Kelly P, Chung DC, Odze RD, et al. Morphology and natural history of familial adenomatous polyposis-associated dysplastic fundic gland polyps. Histopathology. 2014;65(3):353–62.
  54. Aarnio M, Salovaara R, Aaltonen LA, Mecklin JP, Jarvinen HJ. Features of gastric cancer in hereditary non-polyposis colorectal cancer syndrome. Int J Cancer. 1997;74(5):551–5.
  55. Chung DC, Rustgi AK. The hereditary nonpolyposis colorectal cancer syndrome: genetics and clinical implications. Ann Intern Med. 2003;138(7):560–70.
  56. Mecklin JP, Jarvinen HJ, Peltokallio P. Cancer family syndrome. Genetic analysis of 22 Finnish kindreds. Gastroenterology. 1986;90(2):328–33.
  57. Park YJ, Shin KH, Park JG. Risk of gastric cancer in hereditary nonpolyposis colorectal cancer in Korea. Clin Cancer Res. 2000;6(8):2994–8.
  58. Kimura K, Shinmura K, Hasegawa T, Beppu Y, Yokoyama R, Yokota J. Germline p53 mutation in a patient with multiple primary cancers. Jpn J Clin Oncol. 2001;31(7):349–51.
  59. Kleihues P, Schauble B, zur Hausen A, Esteve J, Ohgaki H. Tumors associated with p53 germline mutations: a synopsis of 91 families. Am J Pathol. 1997;150(1):1–13.
  60. Jenne DE, Reimann H, Nezu J, Friedel W, Loff S, Jeschke R, et al. Peutz–Jeghers syndrome is caused by mutations in a novel serine threonine kinase. Nat Genet. 1998;18(1):38–43.
  61. Giardiello FM, Brensinger JD, Tersmette AC, Goodman SN, Petersen GM, Booker SV, et al. Very high risk of cancer in familial Peutz–Jeghers syndrome. Gastroenterology. 2000;119(6):1447–53.
  62. Noda M, Kodama T, Atsumi M, Nakajima M, Sawai N, Kashima K, et al. Possibilities and limitations of endoscopic resection for early gastric cancer. Endoscopy. 1997;29(5):361–5.
  63. Carneiro F, David L, Seruca R, Castedo S, Nesland JM, Sobrinho-Simoes M. Hyperplastic polyposis and diffuse carcinoma of the stomach. A study of a family. Cancer. 1993;72(2):323–9.
  64. Seruca R, Carneiro F, Castedo S, David L, Lopes C, Sobrinho-Simoes M. Familial gastric polyposis revisited. Autosomal dominant inheritance confirmed. Cancer Genet Cytogenet. 1991;53(1):97–100.
  65. Correa P. A human model of gastric carcinogenesis. Cancer Res. 1988;48(13):3554–60.
  66. Lauwers GY, Riddell RH. Gastric epithelial dysplasia. Gut. 1999;45(5):784–90.
  67. Yakirevich E, Resnick MB. Pathology of gastric cancer and its precursor lesions. Gastroenterol Clin North Am. 2013;42(2):261–84.
  68. Kasuga A, Yamamoto Y, Fujisaki J, Okada K, Omae M, Ishiyama A, et al. Clinical characterization of gastric lesions initially diagnosed as low-grade adenomas on forceps biopsy. Dig Endosc. 2012;24(5):331–8.
  69. Ghandur-Mnaymneh L, Paz J, Roldan E, Cassady J. Dysplasia of nonmetaplastic gastric mucosa. A proposal for its classification and its possible relationship to diffuse-type gastric carcinoma. Am J Surg Pathol. 1988;12(2):96–114.
  70. Carneiro F, Huntsman DG, Smyrk TC, Owen DA, Seruca R, Pharoah P, et al. Model of the early development of diffuse gastric cancer in E-cadherin mutation carriers and its implications for patient screening. J Pathol. 2004;203(2):681–7.
  71. Borrmann R. Geshwulste des Magens und Duodenums. In: Henke F, Lubarsch O, editors. Handbuch der Speziellen Patho-logischen Anatomie und Histologie. Berlin: Springer-Verlag; 1926. p. 865.
  72. Tan IB, Ivanova T, Lim KH, Ong CW, Deng N, Lee J, et al. Intrinsic subtypes of gastric cancer, based on gene expression pattern, predict survival and respond differently to chemotherapy. Gastroenterology. 2011;141(2):476–85, 485.e1–11.
  73. Shah MA, Khanin R, Tang L, Janjigian YY, Klimstra DS, Gerdes H, et al. Molecular classification of gastric cancer: a new paradigm. Clin Cancer Res. 2011;17(9):2693–701.
  74. Ming SC. Gastric carcinoma. A pathobiological classification. Cancer. 1977;39(6):2475–85.
  75. Goseki N, Takizawa T, Koike M. Differences in the mode of the extension of gastric cancer classified by histological type: new histological classification of gastric carcinoma. Gut. 1992;33(5):606–12.
  76. Carneiro F, Seixas M, Sobrinho-Simoes M. New elements for an updated classification of the carcinomas of the stomach. Pathol Res Pract. 1995;191(6):571–84.
  77. Laurén P. The two histological main types of gastric carcinoma: diffuse and so-called intestinal-type carcinoma—an attempt at a histo-clinical classification. Acta Pathol Microbiol Scand. 1965;64:31–49.
  78. Fenoglio-Preiser C, Carneiro F, Correa P, Guilford P, Lambert R, Megraud F, et al. Tumors of the stomach. In: Hamilton SR, Aaltonen LA, editors. World health organization classification of tumours: pathology and genetics of tumours of the digestive system. Lyon: IARCPress; 2000. pp. 37–52.
  79. Luebke T, Baldus SE, Grass G, Bollschweiler E, Thiele J, Dienes HP, et al. Histological grading in gastric cancer by Ming classification: correlation with histopathological subtypes, metastasis, and prognosis. World J Surg. 2005;29(11):1422–7 (discussion 8).
  80. Lee H, Tang LH, Veras EF, Klimstra DS. The prevalence of pancreatic acinar differentiation in gastric adenocarcinoma: report of a case and immunohistochemical study of 111 additional cases. Am J Surg Pathol. 2012;36(3):402–8.
  81. Liu Z, Mira JL, Cruz-Caudillo JC. Primary gastric choriocarcinoma: a case report and review of the literature. Arch Pathol Lab Med. 2001;125(12):1601–4.
  82. Niederau C, Sobin LH. Secondary tumors of the stomach. In: Hamilton SR, Aaltonen LA, editors. World health organization classification of tumours: pathology and genetics of tumours of the digestive system. Lyon: IARC Press; 2000. pp. 66–7.
  83. Oda, Kondo H, Yamao T, Saito D, Ono H, Gotoda T, et al. Metastatic tumors to the stomach: analysis of 54 patients diagnosed at endoscopy and 347 autopsy cases. Endoscopy. 2001;33(6):507–10.
  84. Spicer J, Benay C, Lee L, Rousseau M, Andalib A, Kushner Y, et al. Diagnostic accuracy and utility of intraoperative microscopic margin analysis of gastric and esophageal adenocarcinoma. Ann Surg Oncol. 2014;21(8):2580–6.
  85. Edge S, Byrd DR, Compton CC, Fritz AG, Greene FL, Trotti A, editors. AJCC cancer staging manual. 7th ed. 2010.
  86. Mansour JC, Tang L, Shah M, Bentrem D, Klimstra DS, Gonen M, et al. Does graded histologic response after neoadjuvant chemotherapy predict survival for completely resected gastric cancer? Ann Surg Oncol. 2007;14(12):3412–8.
  87. Ryan R, Gibbons D, Hyland JM, Treanor D, White A, Mulcahy HE, et al. Pathological response following long-course neoadjuvant chemoradiotherapy for locally advanced rectal cancer. Histopathology. 2005;47(2):141–6.
  88. Correa P, Shiao YH. Phenotypic and genotypic events in gastric carcinogenesis. Cancer Res. 1994;54(7 Suppl):1941s-3s.
  89. Fuchs CS, Mayer RJ. Gastric carcinoma. N Engl J Med. 1995;333(1):32–41.
  90. Wright PA, Williams GT. Molecular biology and gastric carcinoma. Gut. 1993;34(2):145–7.
  91. Uemura N, Okamoto S, Yamamoto S, Matsumura N, Yamaguchi S, Yamakido M, et al. Helicobacter pylori infection and the development of gastric cancer. N Engl J Med. 2001;345(11):784–9.
  92. Bertuccio P, Chatenoud L, Levi F, Praud D, Ferlay J, Negri E, et al. Recent patterns in gastric cancer: a global overview. Int J Cancer. 2009;125(3):666–73.
  93. Richards FM, McKee SA, Rajpar MH, Cole TR, Evans DG, Jankowski JA, et al. Germline E-cadherin gene (CDH1) mutations predispose to familial gastric cancer and colorectal cancer. Hum Mol Genet. 1999;8(4):607–10.
  94. Keller G, Grimm V, Vogelsang H, Bischoff P, Mueller J, Siewert JR, et al. Analysis for microsatellite instability and mutations of the DNA mismatch repair gene hMLH1 in familial gastric cancer. Int J Cancer. 1996;68(5):571–6.
  95. Toyota M, Ahuja N, Suzuki H, Itoh F, Ohe-Toyota M, Imai K, et al. Aberrant methylation in gastric cancer associated with the CpG island methylator phenotype. Cancer Res. 1999;59(21):5438–42.
  96. Lei Z, Tan IB, Das K, Deng N, Zouridis H, Pattison S, et al. Identification of molecular subtypes of gastric cancer with different responses to PI3-kinase inhibitors and 5-fluorouracil. Gastroenterology. 2013;145(3):554–65.
  97. Boussioutas A, Li H, Liu J, Waring P, Lade S, Holloway AJ, et al. Distinctive patterns of gene expression in premalignant gastric mucosa and gastric cancer. Cancer Res. 2003;63(10):2569–77.
  98. Wang K, Kan J, Yuen ST, Shi ST, Chu KM, Law S, et al. Exome sequencing identifies frequent mutation of ARID1A in molecular subtypes of gastric cancer. Nat Genet. 2011;43(12):1219–23.
  99. Hamilton SR, Aaltonen LA, editors. World health organization classification of tumours: pathology and genetics of tumours of the digestive system. Lyon: IARC Press; 2000.

 

[contact-form-7 id=»5168″ title=»Контактная форма 1″]

0

Добавить комментарий

Войти с помощью: 

Ваш e-mail не будет опубликован. Обязательные поля помечены *